MedTrace Logo

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

NCT04252885 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2020-07-01

No results posted yet for this study

Summary

The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .

Conditions

  • Coronavirus Infections

Interventions

DRUG

Lopinavir and Ritonavir Tablets

As indicated in arm/group descriptions

DRUG

Arbidol

As indicated in arm/group descriptions

Sponsors & Collaborators

  • Guangzhou 8th People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-28
Primary Completion
2020-04-30
Completion
2020-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252885 on ClinicalTrials.gov